Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
Journal article
Kent D. et al, (2024), Hepatology (Baltimore, Md.)
-
Improving the representativeness of UK’s national COVID-19 Infection Survey through spatio-temporal regression and post-stratification
Journal article
Pouwels KB. et al, (2024), Nature Communications, 15
-
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells
Journal article
Baugh R. et al, (2024), Journal for ImmunoTherapy of Cancer, 12, e008460 - e008460
-
Optimized protocol for CRISPR knockout of human iPSC-derived macrophages
Journal article
Navarro-Guerrero E. et al, (2024), STAR Protocols, 5, 102903 - 102903
-
Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study
Journal article
Bešević J. et al, (2024), Journal of Epidemiology and Community Health, 78, 105 - 108